WaveMan
WaveMan · Company
INKT · Mink Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

INKT MiNK Therapeutics (INKT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001840229
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed

What the filings say about INKT

Insiders, 180 days
-$92.4K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$73.3K
1 notice

MiNK Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, MiNK Therapeutics, Inc. insiders sold a net $92.4K of stock across 27 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Buell Jennifer
Chief Executive Officer
SELL
2026-10-14 SECtraded 2026-10-12
6,938
$73.3K
+4.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 9.4% of the 74,195 shares held after it.
  • No other insider sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Buell Jennifer sold about $73.3K of INKT on Oct 12, 2026, the largest insider sale at the company since 2023; 13 funds added in the latest 13F quarter.
Ryan Barbara
Director
SELL
2026-06-05 SECtraded 2026-06-04
1,000
$12.8K
-8.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 10, 2026.
  • The trade is 4.6% of the 21,969 shares held after it.
  • No other insider sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ryan Barbara sold about $12.8K of INKT on Jun 4, 2026, the largest insider sale at the company since 2023; 13 funds added in the latest 13F quarter.
Ryan Barbara
Director
SELL
2026-06-05 SECtraded 2026-06-04
500
$6.3K
-8.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 10, 2026.
  • The trade is 2.2% of the 22,969 shares held after it.
  • No other insider sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ryan Barbara sold about $6.3K of INKT on Jun 4, 2026; 13 funds added in the latest 13F quarter.
Ryan Barbara
Director
SELL
2026-03-11 SECtraded 2026-03-10
500
$7.7K
+1.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Mar 9, 2026.
  • The trade is 2.5% of the 20,406 shares held after it.
  • No other insider sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ryan Barbara sold about $7.7K of INKT on Mar 10, 2026, the largest insider sale at the company since 2023; 13 funds added in the latest 13F quarter.
Ryan Barbara
Director
SELL
2026-03-11 SECtraded 2026-03-10
500
$7.8K
+1.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Mar 9, 2026.
  • The trade is 2.4% of the 20,906 shares held after it.
  • No other insider sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ryan Barbara sold about $7.8K of INKT on Mar 10, 2026, the largest insider sale at the company since 2023; 13 funds added in the latest 13F quarter.
27 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 22 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$92.4K over 180 days
-$73.3K over 90 days
more than 55% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 77% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.3% of the float short (float per yahoo 2026-10-27) · 2.4 days to cover · settled 2026-10-15
below 73% of Pharma & Biotech
What changed in the last 30 days
Oct 14Chief Executive Officer Buell Jennifer sold $73.3K (Oct 12)
Oct 13Officer Buell Jennifer filed to sell $73.3K by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch INKT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-26.3%12M
-40%-24%-9%+6%2025-102025-122026-022026-042026-062026-082026-10 2026-10-12 · Buell Jennifer sold $73.3K2026-06-04 · Ryan Barbara sold $12.8K2026-03-10 · Ryan Barbara sold $7.8K2026-03-10 · Ryan Barbara sold $7.7K2026-06-04 · Ryan Barbara sold $6.3K2026-03-10 · Ryan Barbara sold $4.6K2026-02-27 · Ryan Barbara sold $4.3K2026-03-09 · Ryan Barbara sold $2.0K2026-03-02 · Ryan Barbara sold $1.1K2026-10-13 · Buell Jennifer filed to sell $73.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns INKT: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
68,660 sh
$802.6K
DNB Asset Management AS
55,142 sh
$644.6K
Longbow Finance SA
16,667 sh
$194.8K
GEODE CAPITAL MANAGEMENT, LLC
15,573 sh
$182.1K
CITADEL ADVISORS LLC
15,440 sh
$180.5K

Congress trades in INKT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

INKT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Buell Jennifer
Filed 2026-10-13
$73.3K

INKT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$78.7K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$5.2K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$80.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$179.8K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$23.2K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$620.4K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
0 active
1
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $92.4K sold by insiders over 180 days, 13 funds added last quarter, $73.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

INKT financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$6.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-187.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-13.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$12.6M-$11.3M-$22.9M-$30.9M
Net income-$12.5M-$10.8M-$22.5M-$28.0M
EPS (diluted)-2.93-2.86-6.54-0.83
Operating cash flow-$5.9M-$9.6M-$15.8M-$18.9M
Cash$13.4M$4.6M$3.4M$19.6M
SEC XBRL, fiscal years, as known on 2026-10-28

INKT Stock Sonar score 3/7 axes

Find similar shapesCompare

INKT ranks highest on risk and compliance (71st percentile) and insider conviction (27th), and lowest on institutional and government (23rd), among Pharma & Biotech peers.

Insider conviction
27
Inputs
  • Net Form 4 buying (codes P and S), 180d-$92K · 54 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
23
Inputs
  • Funds adding, latest quarter13 · 23 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
71
Inputs
  • Short interest, % of float+2.3% · 71 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

INKT filings, in plain words

Are MiNK Therapeutics insiders buying or selling INKT?

In the 180 days to 2026-10-28, MiNK Therapeutics insiders were net sellers, a net $92.4K across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of INKT?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $73.3K of stock; the latest, by Buell Jennifer, was filed 2026-10-13.

Read the full summary

In the 180 days to 2026-10-28, MiNK Therapeutics insiders were net sellers of INKT, a net $92.4K across purchases and sales reported on Form 4 by 2 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $73.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies